Please login to the form below

Not currently logged in
Email:
Password:

Transition Therapeutics

This page shows the latest Transition Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Transition takes on Lilly muscle-boosting drug

Transition takes on Lilly muscle-boosting drug

Eli Lilly has licensed rights to an experimental drug that builds muscle to Canada's Transition Therapeutics. ... In a statement, Transition limited itself to saying that the profile of the drug "creates a number of development opportunities.".

Latest news

  • Transition halts diabetes drug development

    Transition halts diabetes drug development. Transition Therapeutics has discontinued development of a new therapy for type 2 diabetes after it failed to meet efficacy endpoints. ... Transition Therapeutics has discontinued development of a potential new

  • Lilly halts Alzheimer's drug development

    Only days ago, Elan announced its own disappointing results for another Alzheimer's drug targeting amyloid plaques that the company is developing with Transition Therapeutics.

  • FDA approves generic Aricept for dementia

    Elan stops Alzheimer's drug trial after deaths. Dublin-based Elan, and its partner Transition Therapeutics, have removed two high doses of their experimental orally-administered Alzheimer's therapy from a

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    Transition Therapeutics with the out-licence of the phase II ready selective androgen receptor modulator TT701 to Transition. ... 105.5. Eli Lilly/ Transition Therapeutics. Licence agreement. For TT701 a selective androgen receptor modulator in P2 for

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    143. Lilly / Transition Therapeutics. Licence, collaboration and option‡. TT-601 for osteoarthritis pain (preclinical). ... EU. ‡ Payable to Transition Therapeutics if Lilly exercises its option to re-acquire at clinical proof of concept.

  • Pharma deals during July 2013 Pharma deals during July 2013

    Lilly entered into a deal with Transition Therapeutics with an interesting structure that allows the large pharma to buy back the asset, TT-601 for the treatment of pain in osteoarthritis, ... If Lilly exercises its option to reacquire the rights to

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    London, UK-based Orchard Therapeutics has appointed Mark Rothera as its new president and chief executive officer at a time when the group progresses its clinical pipeline. ... Prior to his new role, Rothera served as chief commercial officer at PTC

  • Crescendo Biologics appoints Peter Pack as CEO Crescendo Biologics appoints Peter Pack as CEO

    Crescendo is now shifting its focus to oncology with novel VH-based checkpoint modulators and humabody drug conjugate (HDC) therapeutics. ... He said: “ The transition to a product-oriented oncology therapeutics company is a pivotal moment in

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics